Semaglutide improves blood sugar and weight in people with schizophrenia and prediabetes

People with schizophrenia often face extra health challenges. Many take medications that can affect their weight and blood sugar. This group also has a higher risk for diabetes and heart disease. A new study offers hope for managing these risks without stopping necessary mental health treatment. The research focuses on semaglutide, a medication known for helping with weight and blood sugar control. This drug is already used for diabetes and obesity. Now, doctors are looking at whether it helps people with schizophrenia too. The study involved 154 adults. Half took semaglutide once a week. The other half took a placebo, which looks like the real drug but has no active medicine. All participants were overweight or obese and already taking second-generation antipsychotics for their mental health. These medications are standard care but can cause weight gain and insulin problems. The researchers wanted to see if adding semaglutide could fix these issues. They followed the patients for 30 weeks. This is a long time to see real changes in the body. The results were clear for several key measures. Fasting glucose levels dropped significantly. This means blood sugar was lower when people woke up in the morning. Insulin sensitivity improved by a large amount. This means the body used insulin better to move sugar into cells. Insulin resistance also went down. This is a major win for preventing diabetes. Weight loss was substantial. Participants lost an average of 9.2 kilograms. This is a big change that can lower heart disease risk. The study found that most of the improvement in blood sugar came from losing weight. This makes sense because losing weight helps the body handle sugar better. Some other measures showed small changes. Fasting insulin and C-peptide levels showed a trend toward improvement but did not reach the strict statistical threshold. Beta-cell function saw a modest increase but was not statistically significant. Safety was monitored closely throughout the 30 weeks. No serious side effects were reported. No one had to stop the drug early due to problems. The study did not report specific adverse events or discontinuation rates. This suggests the drug was well tolerated in this group. However, this is one study with a limited number of people. The results are promising but not a guarantee for every patient. Doctors should discuss these findings with their patients. Semaglutide could be a useful tool for managing metabolic health. It might help prevent diabetes in people on antipsychotics. The medication is not a cure for schizophrenia. It is an add-on therapy to improve overall health. Patients should talk to their doctors about their specific situation. Weight loss and better blood sugar control are important goals. This research supports using semaglutide as a strategy for high-risk patients. It offers a path to better health without compromising mental health care.